FSD Pharma

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

TORONTO--(BUSINESS WIRE)-- #FSDPharma--FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that, subject to court certification and other customary conditions, it has entered into a definitive settlement agreement (the "Settlement Agreement") with respect to the class action litigation commenced by a plaintiff shareholder in the Ontario Superior Court of Justice in February 2019 relating to the build-out of its facility in Cobourg, Ontario (the "Settled Action"). The Com

FSD Pharma Announces Settlement of Class Action Proceeding

TORONTO--(BUSINESS WIRE)-- #HUGE--FSD Pharma Inc. (Nasdaq: HUGE) (“FSD Pharma” or the “Company”), today announced the closing of previously announced definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate Voting Shares of the Company (“Shares”) and warrants to purchase 3,454,543 Shares (collectively, the “Securities”) at a purchase price of US$2.20 per Share in a registered direct offering. The warrants have an exercise price of US$2.60 per Share, are immediatel

FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering

TORONTO--(BUSINESS WIRE)-- #FSDDF--FSD Pharma Inc. (Nasdaq: HUGE) (“FSD Pharma” or the “Company”), today announced that it has entered into definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate Voting Shares of the Company (“Shares”) and warrants to purchase 3,454,543 Shares (collectively, the “Securities”) at a purchase price of US$2.20 per Share in a registered direct offering. The warrants will have an exercise price of US$2.60 per Share, will be immediately

FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering

TORONTO--(BUSINESS WIRE)-- #FSDDF--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has authorized the initiation of a Phase 2 study for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the “FSD201 COVID-19 Trial”). The company is expected to start dosing patients in October 2020. We believe FSD201 may have the potential

FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients

TORONTO--(BUSINESS WIRE)-- #FSDDF--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has submitted to the U.S.

FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19

TORONTO--(BUSINESS WIRE)-- #FSDDF--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today reported that management’s discussion and analysis of financial condition and results of operations (“MD&A”) for the three months ended June 30, 2020 have been filed and can be viewed on the Company’s SEDAR profile at www.sedar.com.

FSD Pharma Reports Second Quarter 2020 Financial Results

TORONTO--(BUSINESS WIRE)-- #FSDDF--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) announces the closing of a previously announced agreement with investors for the purchase and sale of 2,762,430 Class B Subordinate Voting Shares of the Company (“Shares”) and warrants to purchase 1,381,215 Shares (collectively, the “Securities”) at a purchase price of US$3.62 per Share in a registered direct offering.

FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors

Vancouver, British Columbia--(Newsfile Corp. - July 31, 2020) - FSD Pharma Inc.

FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video

TORONTO--(BUSINESS WIRE)-- #FSDDF--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”), today announced that it has entered into definitive agreements with investors for the purchase and sale of 2,762,430 Class B Subordinate Voting Shares of the Company (“Shares”) and warrants to purchase 1,381,215 Shares (collectively, the “Securities”) at a purchase price of US$3.62 per Share in a registered direct offering.

FSD Pharma Inc. Announces US$10 Million Registered Direct Offering

TORONTO--(BUSINESS WIRE)-- #FSDDF--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that it has notified Health Canada of the Company’s decision to forfeit the licenses of its wholly-owned subsidiary, FV Pharma, Inc.

FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.

Vancouver, British Columbia--(Newsfile Corp. - June 23, 2020) -  FSD Pharma Inc. (NASDAQ: HUGE)  (CSE: HUGE) (FSE: 0K9), a specialty, biotech pharmaceutical R&D company, focused on developing, over time, multiple applications of its lead compound FSD201, has announced favorable topline results from its Phase I first-in-human safety and tolerability study of ultra-micronized palmitolylethanolamide or PEA. This randomized, double-blind, placebo-controlled study of PEA, or FSD201, was conducted at the Alfred Hospital, part of the Alfred...

InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.com

TORONTO--(BUSINESS WIRE)-- #FSDDF--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201. This single-site study was conducted at the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia and enrolled 48 healthy adult men and women. The trial sequential

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

FSD Pharma Jumps On COVID-19 Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma

Shares of FSD Pharma tripled Wednesday after the small-cap biotech company announced plans to study a potential coronavirus treatment. The drug is called ultramicronized PEA.

Covid Report: Small Biotech Triples On Plans To Test A Coronavirus Drug

FSD Pharma Inc. (NASDAQ: HUGE) shares absolutely exploded on Wednesday morning after the company received a key update from the U.S.

Why This COVID-19 Stock More Than Tripled

Shares of FSD Pharma Inc (NASDAQ: HUGE) are advancing strongly Wednesday following an announcement regarding a potential COVID-19 drug.

FSD Pharma Jumps 200% After FDA Nod For Initiating Proof-Of-Concept Study Of COVID-19 Treatment

FSD Pharma Inc (NASDAQ: HUGE) has netted itself more than $7.7 million through the sale of its 12% equity interest in Cannara Biotech Inc (OTC: LOVFF) to a consortium of that included entities controlled by members of the Cannara board and senior management.

FSD Pharma Sells Cannara Biotech Stake, Netting More Than $7.7M

FSD Pharma Inc (CSE: HUGE) (OTC: FSDDF) said Monday that its Class B Subordinate Voting Shares have been accepted for listing on the NASDAQ Capital Market under the ticker "HUGE.

FSD Pharma To Start Trading On Nasdaq This Week

FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) said Monday it has obtained approval for its Class B subordinate shares to list on the Nasdaq Capital Market.

News for FSD Pharma Stock (HUGE)